01 1Bioquim 02 1Basic Nutrition 03 1Willow Birch Pharma 04 1Gangwal Healthcare 05 1Sumar Biotech 06 1Anlon Healthcare Ltd 07 1Chongqing DaXin Pharmaceutical 08 1Gurvey & Berry 09 1Hanways Chempharm 10 1Jin Dun Medical 11 1Mac-Chem Products (India) Pvt.Ltd 12 2Shenzhen GSH Bio-tech Co., Ltd 13 1Summit Ingredients 14 1Xian Tian Guangyuan Biotech 15 1Zhejiang Hisun Chemical Co., Ltd
Hepatology 51: 19611971, 2010
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest
Disclosures: Sai Santosh Babu Komakula: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Wei Chen: Nothing to Disclose, Romain Desert: Nothing to Disclose, Hui Han: Nothing to Disclose, Zhuolun Song: Nothing to Disclose, Sukanta Das: Nothing to Disclose, Dipti Athavale: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Chao Wang: Nothing to Disclose, Dan Lantvit: Nothing to Disclose, Abid Anwar: Nothing to Disclose, Natalia Nieto: Nothing to Disclose 2637 PRIMARY GRAFT DYSFUNCTION AND MAJOR ADVERSE CARDIAC EVENTS AFTER HEPATITIS C VIREMIC HEART TRANSPLANTATION TO AVIREMIC RECIPIENTS Ritika Mazumder 1 Sarah Khan 1 Sakthi Surya Prakash 1 Qijun Yang 1 Omar Sims 1 Randall Starling 1 William Carey 1 , 1 Cleveland Clinic Foundation Background: Although direct-acting antiviral therapy (DAA) has enabled successful use of hepatitis C (HCV) positive allografts with favorable short-term outcomes, there is a notable absence of studies comprehensively examining cardiac events following HCV viremic heart transplantation
